U.S. Markets open in 3 hrs 46 mins
  • Gold

    1,786.70
    +1.80 (+0.10%)
     
  • EUR/USD

    1.1646
    -0.0007 (-0.0582%)
     
  • 10-Yr Bond

    1.6360
    0.0000 (0.00%)
     
  • Vix

    16.06
    +0.36 (+2.29%)
     
  • GBP/USD

    1.3793
    -0.0032 (-0.2331%)
     
  • USD/JPY

    114.0600
    -0.2690 (-0.2353%)
     
  • BTC-USD

    66,428.52
    +2,439.37 (+3.81%)
     
  • CMC Crypto 200

    1,567.71
    +86.91 (+5.87%)
     
  • FTSE 100

    7,200.18
    -22.92 (-0.32%)
     
  • Nikkei 225

    28,708.58
    -546.97 (-1.87%)
     

Edited Transcript of CO.N earnings conference call or presentation 25-Feb-21 1:00pm GMT

·11 min read

Q3 2021 Global Cord Blood Corp Earnings Call Central Feb 26, 2021 (Thomson StreetEvents) -- Edited Transcript of Global Cord Blood Corp earnings conference call or presentation Thursday, February 25, 2021 at 1:00:00pm GMT TEXT version of Transcript ================================================================================ Corporate Participants ================================================================================ * Bing Chuen Chen Global Cord Blood Corporation - CFO & Director * Cathy Bai Global Cord Blood Corporation - VP of Corporate Finance ================================================================================ Conference Call Participants ================================================================================ * Cyrille Pichot * Sandy Mehta Value Investment Principals Ltd. - Director ================================================================================ Presentation -------------------------------------------------------------------------------- Operator [1] -------------------------------------------------------------------------------- Welcome everyone to Global Cord Blood Corporation Earnings Conference Call for the Fiscal Year 2021 Third Quarter. (Operator Instructions) Now I would like to introduce Ms. Cathy Bai, VP of Corporate Finance, to begin the presentation, please. -------------------------------------------------------------------------------- Cathy Bai, Global Cord Blood Corporation - VP of Corporate Finance [2] -------------------------------------------------------------------------------- Thank you, Aaron. Good morning, everyone. Welcome to our fiscal 2021 third quarter earnings conference call. A press release discussing our financial results has already been published and a copy is available on our company's website. During the call, our management team will summarize corporate developments and financial highlights for the quarter. A question-and-answer session will follow. Before we begin, please note that today's discussion will contain forward-looking statements that are subject to certain risks and uncertainties, and actual results could be materially different from these forward-looking statements. Kindly refer to our SEC filings for detailed discussions of potential risks. In interest of time, we will begin with our CEO's remarks, followed by a report of our fiscal 2021 third quarter financials given by our CFO, Mr. Albert Chen. Our management will be available to answer questions during the QA session. To give everyone a chance to ask questions, we'd appreciate if you could ask one question at a time. Today, on behalf of our CEO, Tina, I will read her prepared remarks. Let's begin our presentation. Good morning, ladies and gentlemen. Welcome to our third quarter fiscal 2021 earnings conference call. During the reporting quarter, as the COVID-19 pandemic persisted and caused the on and off partial lockdown, hospitals in our operating markets continue to restrict access. Meanwhile, newborn numbers continue to trend downwards. These combined factors continue to put pressure on client conversion. Despite these challenges, communities continue to adapt to various pandemic measures, and the management team continue to refine the group's resource deployment while adjusting sales and marketing strategies. As a result, we managed to recruit 17,802 new subscribers this quarter in line with management's expectations. By the end of December 2020, our accumulated subscriber base had surpassed 882,000. During the third quarter, the National Health Commission announced the new policy that no cord blood banking license applications will be accepted in 2021 with no further regulatory details provided. Despite the uncertainties surrounding regulation of the cord blood banking industry in China, our past accomplishments have laid a solid foundation in regards to market education and awareness. Thereby enabling the public in our operating markets to be more knowledgeable on existing and potential medical benefits of cord blood stem cells. Under the current circumstances, we are determined to maintain our quality of service, strengthen our brand name, and solidify and expand our hospital channels as we invigorate our frontline teams and continue to penetrate existing markets. At the same time, we will maintain our dialogues with the regulatory bodies as we continue to source and screen new opportunities for business development, to expand our market coverage and lines of service. Looking ahead, the Year of Ox generally does not have a material effect on the overall downtrend in newborn numbers. However, based on our divisions in the past year, we must remain cautious as the COVID-19 pandemic continues to impact short-term newborn numbers and frontline client access and conversion. All things considered, the management team recommends keeping the annual new subscriber target for fiscal 2021 in the range of 62,000 to 67,000. This concludes my remarks regarding our fiscal 2021 third quarter financial results. Thank you for your ongoing support. I will now turn over the call to our CFO, Mr. Albert Chen, to address our financial performance for the reporting quarter. -------------------------------------------------------------------------------- Bing Chuen Chen, Global Cord Blood Corporation - CFO & Director [3] -------------------------------------------------------------------------------- Good morning, everyone. Thank you for joining our call today. In the third quarter, revenues decreased by 13% year-over-year to approximately CNY 291 million, as the decline in new subscribers led to a decrease in revenues from processing fees and other services. Due to the ongoing COVID-19 impact and fewer newborns in our operating markets, the group recruited 17,802 new subscribers in the reporting quarter, representing a decrease of 24% year-over-year. Consequently, revenues generated from processing fees and other services decreased by 24% year-over-year to CNY 165 million, which accounted for approximately 57% of total revenues compared to 65% in the prior year period. By the end of December 2020, our accumulated subscriber base exceeded 882,000. Accordingly, storage fees revenues for the third quarter increased by 8% year-over-year to approximately CNY 126 million. Gross profit in the third quarter decreased by 13% year-over-year to approximately CNY 246 million, while gross margin remained largely stable at 85%. That is because the general cost reduction due to lower volumes were offset by higher raw material and labor costs. Operating income for the third quarter decreased by approximately 19% year-over-year to CNY 124 million. And operating margin was 43% compared to 46% of last year. Depreciation and amortization expenses for the reporting quarter were approximately CNY 12 million, similar to the prior year period. Non-GAAP operating income decreased by 17% year-over-year to approximately CNY 136 million. Non-GAAP operating margin was 47% in the reporting quarter. Research and development expenses in the third quarter increased to CNY 9 million from CNY 6 million in the prior year period. As we continue to support ongoing research efforts and launch of new research initiatives. During the reporting quarter, higher advertising and promotional expenses were partially offset by lower staff remuneration as we trimmed down our sales force headcount. As a result, sales and marketing expenses was down by 9% year-over-year. And as a percentage of revenue, it now represents approximately 24% of revenue as compared to 23% of last year. General and administrative expenses decreased by more than 8% year-over-year to CNY 44 million, mainly due to reduced staff costs and professional fees, but partially offset by higher provisions. General and administrative expenses as a percentage of revenue was 15% compared to 14% of last year. In the third quarter, we recognized an approximately CNY 6 million increase in fair value of equity securities or mark-to-market gain as compared to a mark-to-market gain of CNY 8 million of last year. All in all, income before income tax for the third quarter decreased by 19% year-over-year to approximately CNY 139 million. Income tax expense for the third quarter was CNY 21 million. Net income attributable to the company's shareholders decreased by approximately 20% year-over-year to CNY 117 million. Net margin for the third quarter was 40%. Basic and diluted earnings per ordinary share for the reporting quarter was CNY 0.96. These are the highlights of our third quarter results. We are now happy to turn to the floor for any questions. ================================================================================ Questions and Answers -------------------------------------------------------------------------------- Operator [1] -------------------------------------------------------------------------------- (Operator Instructions) Our first question is Sandy Mehta, Value Investment Principals. -------------------------------------------------------------------------------- Sandy Mehta, Value Investment Principals Ltd. - Director [2] -------------------------------------------------------------------------------- Now that COVID is -- has receded quite a bit. Do you expect subscriber growth going forward to pick up? -------------------------------------------------------------------------------- Bing Chuen Chen, Global Cord Blood Corporation - CFO & Director [3] -------------------------------------------------------------------------------- Thank you for the questions. I think the current market situations reflect couple of issue, which we need to address. Obviously, the overall impact with respect to COVID has subsided substantially, save for the fact that there are still mini outbreak here and there, on and off, which kind of depressing to a certain extent. But I think the challenges that we are facing right now is related to the hospital access, which really is pushing us away from a lot of normal client interactions. And in order to address those, we have migrated to online platform and rely on a lot of additional marketing initiatives to maintain active in terms of client recruitment. But right now, I think it will be too early to tell as to when life will be going back to normal. In other words, it will be hard to speculate as to when we will be able to regain normal access via our hospital's channel. So that is obviously an uncertainty that we are facing, and we are trying our very best to address those issues. The other issue, which has more to do with the macro environment is the overall number of babies born in Beijing, Guangdong as well as Zhejiang, are still in a downtrend. And obviously, the impact is somehow mitigated or offset by, for example, factors such as globalized -- not globalization, I mean urbanizations, which is -- which helped to ease the pain a little. But as we pointed out in our CEO remarks, we are not extremely optimistic with respect to the number of babies born in the Year of the Ox. So I guess, right now, we are currently still taking a relatively cautious approach. And in terms of outlook, obviously, we will update our full year guidance when we announce our full year results in June. But right now, I think we are optimistic. I mean, we are cautiously optimistic. That's probably the best way to put it. -------------------------------------------------------------------------------- Operator [4] -------------------------------------------------------------------------------- Our next question is Cyrille Pichot from Altimeo Asset Management. -------------------------------------------------------------------------------- Cyrille Pichot, [5] -------------------------------------------------------------------------------- So I have 2 small questions. The first one is regarding potential acquisition. I mean, did you -- because you are looking at some acquisition, you started a few years ago. But as of today, there is nothing announced regarding a potential acquisition. Do you expect that potentially you will announce something in the near future would be maybe good for -- to diversify your business in terms of geographic and business also? And my second question is regarding capital markets. As you perfectly know, there is a threat of the listing from the U.S. exchange for Chinese U.S.-listed company. A lot of Chinese U.S.-listed companies have implemented a secondary listing in Hong Kong. Do you expect potentially in the future to take care of that because it's a risk, I think, for U.S. shareholders. And to mitigate this risk would be good and cautious to get a secondary listing. -------------------------------------------------------------------------------- Bing Chuen Chen, Global Cord Blood Corporation - CFO & Director [6] -------------------------------------------------------------------------------- Thank you for the questions. With respect to the M&A initiatives. There are currently -- we are looking at several interesting opportunities right now. Obviously, this may still be too early to tell whether those opportunities will be materialized. I don't anticipate that -- we -- at least we haven't reached a stage that we are -- that we intend to enter into any definitive agreements, but we are certainly looking at something quite interesting right now. And it basically involved by first -- expanding our service portfolio, I should say -- fair to say, fair to say. With respect to the capital market plan, obviously, there is rules and regulation from the prior administrations with respect to the -- targeting some U.S.-listed issuers or foreign issuer listed in U.S., I should say. So we are also monitoring the situations. To answer your question in short, is that right now, we don't have an immediate plan to seek a separate listing somewhere else, but sure, we will keep that option open for the time being. -------------------------------------------------------------------------------- Operator [7] -------------------------------------------------------------------------------- Our next question is [Ken Oliver] from (inaudible). -------------------------------------------------------------------------------- Unidentified Analyst, [8] -------------------------------------------------------------------------------- Can you please share your new subscriber breakdown by region and payment options during the quarter as well? -------------------------------------------------------------------------------- Bing Chuen Chen, Global Cord Blood Corporation - CFO & Director [9] -------------------------------------------------------------------------------- Thank you for the questions. In terms of new subscriber geographical breakdown, approximately 68% of our new subscribers signed up in the third quarter were derived from our Guangdong market, 22% came from Zhejiang and the remaining 10% came from Beijing. In terms of payment option breakdown, the upfront payment accounted for approximately 41% of our total new subscribers signed up in the third quarter of fiscal 2021, normal payment options about 27%. And other options plus installment account for basically the balance. -------------------------------------------------------------------------------- Operator [10] -------------------------------------------------------------------------------- (Operator Instructions) There are currently no more questions. Now I'll pass back to turn to Cathy. Thank you. -------------------------------------------------------------------------------- Cathy Bai, Global Cord Blood Corporation - VP of Corporate Finance [11] -------------------------------------------------------------------------------- Thank you, Aaron. This concludes our earnings conference call for the fiscal 2021 third quarter. Thank you all very much for your participation and ongoing support. Have a great day. Aaron, you may now disconnect.